ASCO 2014: Dr. Walter M. Stadler gives his top picks in genitourinary research
FROM THE ASCO ANNUAL MEETING 2014
1. Abstract LBA2, Christopher Sweeney et al.
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
2. Abstract 5012, Toni K. Choueiri et al.
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
https://abstracts.asco.org/144/AbstView_144_125914.html
3. Abstract 4504, Hans J. Hammers et al.
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
https://abstracts.asco.org/144/AbstView_144_129458.html
4. Abstract 5003, Xabier Garcia-Albeniz et al.
Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.
https://abstracts.asco.org/144/AbstView_144_131550.html
Oncology Practice covered this study from a premeeting press briefing.
5. Abstract 5007, Andrew J. Armstrong et al.
Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic, castration-resistant prostate cancer (mCRPC).
https://abstracts.asco.org/144/AbstView_144_127316.html
Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.